Executive Summary

On May 22, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Hepcludex (bulevirtide-gmod) 8.5 mg for chronic hepatitis delta virus (HDV) infection in adults (with or without compensated cirrhosis) (^[1]) (^[2]). This landmark decision makes Hepcludex the first and only FDA-approved therapy for HDV in the United States (^[1]) (^[2]). Chronic HDV – which occurs only in patients already infected with hepatitis B virus (HBV) – is “the most severe form of viral hepatitis” due to its rapid progression to cirrhosis, liver failure, hepatocellular carcinoma, and death (^[1]) (^[3]). Until now, no HDV-specific treatments were available in the U.S.; historically, pegylated interferon (off-label) was the sole option, with limited efficacy and considerable toxicity (^[4]).

This approval followed years of clinical research, including the pivotal Phase 3 MYR301 trial. In MYR301, 48 weeks of Hepcludex therapy achieved a 48% combined virologic/biochemical response (undetectable HDV RNA and normal ALT) versus only 2% in the delayed-treatment control group (^[5]). By Week 96 and Week 144 of treatment, 36% and 50% of patients on Hepcludex had undetectable HDV RNA, indicating sustained viral suppression with continued therapy (^[6]). Side effects were generally manageable, with the most common adverse reactions being injection-site reactions, headache, abdominal pain, fatigue, and pruritus (^[7]). Notably, the drug’s labeling carries a boxed warning: stopping Hepcludex can cause severe exacerbations of both HDV and HBV, so close monitoring (and HBV antiviral therapy) is required around treatment cessation (^[7]).

The FDA awarded Breakthrough Therapy and Orphan Drug designations to Hepcludex and prioritized its review (^[8]). Under accelerated approval, Hepcludex’s efficacy was judged on surrogate endpoints (HDV RNA decline and ALT normalization) “reasonably likely” to predict clinical benefit (^[5]) (^[9]). FDA’s guidance mandates that Gilead confirm the drug’s long-term clinical benefit in a post-approval trial; Gilead has already initiated such a confirmatory outcomes study (^[10]) (^[11]).

From a market perspective, Hepcludex addresses a major unmet need. In the U.S., HDV co-infection is estimated to affect 2–4% of chronic HBV carriers – roughly 40,000–80,000 Americans (^[12]). Globally, HDV burden is higher: estimates vary widely (from ~12 million as per WHO (^[13]) and regional surveys, up to ~72 million by some analyses (^[14])), reflecting uncertainties in diagnosis. High-prevalence pockets exist (e.g. Mongolia, parts of Africa and Asia (^[15])). The availability of an HDV-specific therapy is expected to spur increased screening of HBV patients for HDV and create a new patient population for treatment. At standard orphan-drug pricing, even a small patient base translates into a substantial revenue opportunity. Analysts anticipate that Hepcludex (and other emerging HDV therapies) could represent a multi-hundred-million-dollar market annually once deployed, as Gilead has aggressively marketed other viral hepatitis treatments.

The approval of Hepcludex has broad implications. For patients and physicians, it fills a critical gap in care (^[16]) (^[17]). For public health, it may prompt guideline changes advocating universal HDV screening in HBV patients. For innovators, it validates the HDV therapeutic field, accelerating pipeline candidates (e.g. lonafarnib, nucleic-acid polymers, new interferons) (^[4]) (^[18]). In summary, the May 2026 FDA decision is a historic milestone for viral hepatitis – the first licensed HDV treatment in the U.S. – and it heralds the opening of a new frontier in combating chronic viral liver disease.

Introduction and Background

Hepatitis Delta Virus (HDV) is a defective satellite virus that depends on hepatitis B virus (HBV) for its life cycle (^[13]) (^[19]). HDV virions use the HBV surface antigen to form their envelope and enter hepatocytes via the sodium taurocholate co-transporting polypeptide (NTCP) receptor (^[20]).Only individuals already infected with HBV (co-infected) or who acquire HBV and HDV simultaneously can become infected with HDV (^[13]). Accordingly, HDV occurs only in chronic HBV carriers.

Clinically, HDV is very aggressive. It induces the most severe form of viral hepatitis, with rapid progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death (^[1]) (^[3]). Compared to HBV monoinfection, HDV co-infection multiplies risks of cirrhosis, HCC, transplant and mortality (^[3]) (^[21]). For example, chronic HBV patients with HDV have a 3–10× higher risk of cirrhosis and liver-related death than HBV alone (^[3]). HDV-infected cirrhotics have ~50% 5-year mortality according to some reports (^[22]) (^[21]). Reflecting its severity, the International Agency for Research on Cancer (IARC) classified HDV as a Group 1 carcinogen, alongside HBV and HCV (^[23]).

Epidemiologically, the global HDV burden is substantial but poorly defined. Recent WHO data (July 2025) estimate HDV at about 5% of the ~250 million people with chronic HBV worldwide — roughly 12 million for HDV (^[13]). A 2024 clinical review estimated 15–20 million (5%–7% of HBV) (^[24]). Higher estimates (30–70 million, or up to 72 million) have been cited using broader seropositivity data (^[14]), though these likely include anti-HDV positives that may not all have active HDV. HDV prevalence is heterogenous: “hotspots” include Mongolia (HDV in ~60% of HBV carriers (^[25]), the highest reported worldwide), western and central Africa, the Middle East, and parts of Eastern Europe. Large countries like China, Russia, Pakistan, Brazil harbor many HDV patients due to population size (^[25]). In low-prevalence regions like Western Europe and North America, HDV is often linked to high-risk groups (e.g. IV drug users, immigrants from endemic areas). In the U.S., studies estimate HDV prevalence at 2–4% of HBV carriers (^[12]), corresponding to about 40–80 thousand Americans with chronic HDV.

Because HDV requires HBV, HBV vaccination (which prevents HBV infection) also prevents HDV. However, existing HBV-infected cohorts (especially in older generations or developing countries) continue to face HDV risk (^[13]). Without vaccination or effective treatments, HDV-associated disease remains a public health concern.

Prior to Hepcludex, therapeutic options were virtually nonexistent. No antiviral had ever been approved specifically for HDV anywhere (until the EU’s conditional approval in 2020). Clinicians have historically relied on off-label use of pegylated interferon-α (pegIFNα) to treat HDV, but response rates are modest (~20–30% achieve a ≥2 log RNA decline) and side effects are serious (^[4]). Nucleotide analogs (tenofovir, etc.) suppress HBV but do not directly inhibit HDV replication (^[26]). Thus for decades pegIFNα was the de facto option (^[4]); it requires 48–96 weeks of therapy, induces frequent flu-like toxicity, and yields sustained virologic response in only a minority. Given these limitations, the absence of any approved HDV therapy has long represented a “major unmet need” (^[27]) (^[4]).

Against this backdrop, the development of Hepcludex (bulevirtide) represents a breakthrough. Bulevirtide is the first-in-class entry inhibitor discovered by Stephan Urban’s team in Heidelberg (^[28]) (^[20]). It binds NTCP on hepatocytes, blocking HBV and HDV from entering cells (^[29]) (^[20]). After initial discovery and studies, bulevirtide (at 2 mg daily) received a conditional marketing authorization in the EU for HDV in July 2020 (^[30]). Gilead Sciences acquired the global rights to bulevirtide in 2021 (through a €1.45 billion acquisition of MYR GmbH) (^[30]), and has since driven its development and commercialization worldwide.

The U.S. approval of Hepcludex is therefore the culmination of a multi-stage process: discovery at an academic center, product development by a biotech (Myr/MYR), acquisition by Gilead, and completion of the pivotal U.S. trials needed for FDA review. This report provides a deep analysis of Hepcludex’s FDA approval and its implications. We cover the scientific background of HDV, the clinical evidence for bulevirtide, regulatory details of the accelerated approval, the market and patient impact, and future directions in HDV therapy. We draw on clinical trial data, expert commentary, public databases, and relevant literature to present a thorough, evidence-based picture of this historic milestone.

Chronic Hepatitis Delta: Disease Burden and Natural History

HDV infection manifests as either coinfection (simultaneous acute HDV and HBV infection) or superinfection (HDV on top of established chronic HBV). Superinfection is the more common path to chronic HDV, often leading rapidly to liver damage. HDV has a high propensity to accelerate disease: patients typically progress to cirrhosis 10–20 years earlier than matched HBV-only patients (^[3]) (^[4]). Observational cohorts report that 30–70% of chronic HDV patients already have cirrhosis at diagnosis, and over 50% die of liver-related causes within 10 years (^[31]) (^[4]). In one analysis, up to 60% of HDV-infected patients died within a decade of diagnosis, emphasizing the urgency of treatment (^[32]).

The pathophysiology of HDV involves the small delta antigen (HDAg) assisting replication of the circular RNA genome. Unique features include farnesylation of HDAg (required for viral assembly) (^[33]) and reliance on the HBV surface antigen as an envelope. Because of this dependence, standard HBV drugs (reverse transcriptase inhibitors) have no effect on HDV RNA. The absence of HBV surface antigen (e.g. via HBV cure) would eliminate HDV, but no curative HBV therapy exists yet. Therefore, controlling HDV requires direct antiviral approaches.

Despite its severity, HDV remains underdiagnosed. Data suggest only ~10% of HBV patients in some systems are screened for HDV (^[34]). Multiple guidelines now recommend universal HDV testing in HBV patients, but awareness is still growing. The first approved drug targeting HDV should further raise awareness: now that therapy exists, physicians will likely start testing every HBsAg-positive patient, especially those with elevated liver enzymes or advanced fibrosis.

Bulevirtide (Hepcludex): Mechanism and Pharmacology

Bulevirtide (marketed as Hepcludex) is a synthetic 47-amino-acid lipopeptide derived from a segment of the pre-S1 domain of the HBV surface antigen (^[20]) (^[29]). It mimics the viral binding region and competitively binds NTCP, the hepatocyte receptor used by HBV and HDV to enter cells (^[29]) (^[20]). By blocking NTCP, bulevirtide prevents new cells from being infected by either virus, effectively halting viral spread. It does not directly kill infected cells or eliminate existing virus rapidly; rather, it keeps the viral load low or undetectable over time by entry inhibition. (In ongoing research, longer-term suppression has sometimes allowed functional cures in subsets of patients who remain RNA-negative off therapy (^[35]).)

Pharmacokinetically, Hepcludex is administered as a once-daily subcutaneous injection. The approved U.S. dose is 8.5 mg/day. (In EU labeling, a 2 mg dose with tenofovir was used conditionally (^[36]); Gilead’s U.S. formulation concentrates the peptide to allow 8.5 mg in one vial). Peak blood levels are reached within 30–60 minutes. The half-life is relatively short, justifying daily dosing. In trials, bulevirtide was generally well tolerated over years of treatment. No dose adjustment is needed for mild-to-moderate renal impairment. Its main action is local (since liver expression of NTCP is high), with minimal systemic metabolism.

The pharmacodynamic effect is reflected primarily in measures of viral replication. In clinical trials, bulevirtide reliably lowered or cleared HDV RNA from the blood when given long-term (^[6]) (^[36]). A dose-response was observed: for example, in an EU study adding bulevirtide to tenofovir, 77% of patients receiving 10 mg achieved undetectable HDV RNA at 24 weeks (vs 50–54% at lower doses) (^[36]). Bulevirtide also has the beneficial effect of preventing new HBV infection of hepatocytes, but it does not directly reduce HBV DNA; thus patients remain on nucleos(t)ide HBV therapy in parallel. If treatment is halted, HDV replication can resume (and indeed FDA labeling warns of severe flares upon discontinuation (^[7])). Therefore, optimal use involves continued daily dosing, with intensive monitoring if therapy is interrupted.

In summary, Hepcludex is a prototype viral-entry inhibitor – a new class of antiviral – uniquely suited to HDV/HBV coinfection. It represents a highly targeted approach: blocking the very first step of the viral life cycle in the liver cells. This mechanism is specific to HBV/HDV and does not affect other viruses, contributing to its favorable safety profile.

Clinical Development and Pivotal Trials

Early and Condition-of-Approval Studies

Clinical development of bulevirtide began in Europe under Myr Pharma. Early Phase 2 trials (~2015–2017) investigating 2 mg and 5 mg daily doses showed strong antiviral activity (HDV RNA declines) and good tolerability (^[37]) (^[36]). Based on these data, in 2020 the European Medicines Agency (EMA) granted conditional approval for Hepcludex 2 mg in adults with chronic HDV and compensated liver disease (^[38]). The conditional authorization was converted to full approval in July 2023 (^[38]) (^[39]). Gilead’s 2021 acquisition of Myr provided the means to scale up trials and manufacturing (^[30]).

The key pivotal trial for U.S. approval was MYR301 (ClinicalTrials.gov NCT03852719). MYR301 was a Phase 3, multi-center, open-label trial in chronic HDV patients (with or without cirrhosis). 150 subjects were randomized 1:1:1 to Hepcludex 2 mg/day, Hepcludex 10 mg/day, or delayed treatment (no antiviral for the first 48 weeks, then switched to bulevirtide) (^[40]). All patients were on concurrent tenofovir or another HBV nucleo(t)ide analog. The primary endpoint was assessed at Week 48.

The primary composite endpoint was a combined virologic-and-biochemical response: HDV RNA <LLOQ (undetectable) or ≥2-log10 IU/mL drop, and normalization of ALT (alanine aminotransferase) at Week 48. It reflected both viral suppression and improvement of liver inflammation. Secondary endpoints included HDV RNA undetectability and ALT normalization separately. Importantly, the trial continued treatment beyond Week 48 (up to 144 weeks) to study durability and to allow all patients eventual bulevirtide exposure (^[40]).

MYR301 Results (Weeks 48–144)

By Week 48, Hepcludex met its primary endpoint with a statistically significant advantage over control. In the Hepcludex 8.5 mg arm (equivalent to the 10 mg study dose after fasting), 48% of patients achieved the combined response, versus only 2% in the delayed-treatment group (^[5]). Similarly, 20% of treated patients had completely undetectable HDV RNA at 48 weeks, versus 0% in controls (^[41]). These results were consistent across subgroups (cirrhotic vs non-cirrhotic) and were highly robust (p-values <0.0001 for key comparisons).

Longer-term follow-up showed further viral clearance with continued therapy. By Week 96, 36% of Hepcludex-treated patients had undetectable HDV RNA, increasing to 50% by Week 144 (^[6]). In contrast, nearly all control patients who eventually switched to delayed treatment had detectable virus if tested. The increase from 20% at Week 48 to 50% at Week 144 indicates that extended therapy continues to convert partial responders to full viral suppression. In fact, Gilead presented data at medical meetings (MYR301 long-term) showing that if HDV RNA becomes undetectable for ≥96 weeks on treatment, it often remains suppressed off treatment for a long time (^[35]). These findings suggest a potential for finite therapy in some patients.

Table 1: Key Efficacy Endpoints from the MYR301 Phase 3 Trial (Hepcludex vs Control)

1. Defined as (HDV RNA undetectable or ≥2 log₁₀ decline) and normal ALT (^[5]). Placebo group crossed to active at Week 48.

Beyond virology, Hepcludex treatment also led to biochemical improvement. In the MYR301 trial, ALT normalized in a significantly higher fraction of patients on bulevirtide than controls at Week 48. (Reported as part of secondary endpoints but not tabulated here; see FDA press for details (^[6]).) In a subset undergoing liver biopsy, Hepcludex showed trends toward histologic improvement as well, although small sample sizes limited statistical power.

Importantly, Hepcludex’s antiviral effect was durable while on therapy. EASL 2025 data showed that 90% of adults who achieved undetectable HDV RNA after 96 weeks of bulevirtide treatment remained undetectable nearly two years off therapy (^[35]). This durability suggests true viral suppression rather than sequence artifacts. However, if treatment is stopped earlier, HDV can rebound. Thus, current practice is to continue Hepcludex indefinitely (or at least for several years) until future trials clarify stopping rules.

Safety and Tolerability

Hepcludex was generally well tolerated. The U.S. label (based on MYR301 and other data) reports the most common adverse reactions (≥10%) as: injection site reactions, headache, abdominal pain, fatigue, and pruritus (^[42]). These events were mostly mild/moderate. In MYR301 and extension studies, few patients discontinued bulevirtide due to side effects. Notably, hypersensitivity reactions (including rare anaphylaxis) occurred; therefore, the label includes a boxed warning about severe flares of hepatitis upon stopping drug (^[7]). This flare warning is specific to HDV/HBV coinfected patients: abrupt withdrawal of viral suppression can cause a rebound of viral replication and liver injury (^[7]). Consequently, treatment interruption must be followed by close monitoring of liver tests, HDV RNA, and HBV DNA, and prompt resumption of therapy or addition of HBV antivirals if necessary (^[7]).

No major laboratory abnormalities or organ-specific toxicities emerged. Bulevirtide does not have renal or hepatic dose adjustments, as its clearance is slow proteolysis and not via cytochrome metabolism. During MYR301, some patients did experience hepatitis flares off-treatment (as expected) but on-treatment liver labs generally improved. In comparative analysis, adverse events occurred at similar rates as placebo or historical controls. Overall, the benefit/risk profile was deemed favorable given the lack of alternatives and the severity of HDV.

FDA Review and Accelerated Approval

Regulatory Pathway

The FDA processed Hepcludex through an accelerated approval in recognition of HDV as a serious condition with unmet need (^[9]) (^[8]). Accelerated approval (established by Congress in 1992 and refined by FDASIA 2012) allows approval based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit (^[9]). For Hepcludex, the surrogate endpoints were reductions in HDV RNA and ALT normalization (markers “reasonably likely” to reflect clinical outcomes in HDV) (^[5]) (^[43]). Indeed, the FDA press release notes the approval was based on HDV RNA reduction and ALT normalization (^[5]), which align with the MYR301 combined endpoint.

As per accelerated approval rules, confirmatory trials are required. The FDA emphasized that “an improvement in disease-related clinical outcomes has not been established” for Hepcludex (^[44]). In other words, while viral and lab surrogates were met, the effect on hard outcomes (e.g. progression to cirrhosis or survival) needs validation. Gilead has already committed to a long-term outcomes study in HDV patients to verify clinical benefit (^[10]). Continued approval of Hepcludex may be contingent on these confirmatory data, following the FDA’s guidance (subsequent studies must show benefit to maintain labeling (^[11]) (^[45])).

In addition, Hepcludex was granted Breakthrough Therapy and Orphan Drug designations. Breakthrough status facilitated close FDA engagement and rolling review; Orphan status provides incentives like market exclusivity. Gilead submitted the new drug application (NDA) for Hepcludex after extensive communication with the agency. The FDA ultimately approved the NDA under Priority Review (completion time ~6 months) and granted accelerated approval on a shorter timeline than standard review.

Approval and Labeling

On May 22, 2026, FDA announced approval of Hepcludex (bulevirtide-gmod) injection, 8.5 mg for adults with chronic HDV infection, without cirrhosis or with compensated cirrhosis (^[1]). The key indication language states: “for the treatment of chronic hepatitis delta virus infection in adults…” (^[46]). This label is identical to the EMA’s except for dose strength. The regimen is daily subcutaneous injection of 8.5 mg as long as benefit is observed, in conjunction with HBV management. The FDA highlights that “continued treatment as long as there is a response” is recommended, since optimal duration is unknown (^[47]).

A boxed warning was included about post-treatment flares of hepatitis D and B (^[7]). The label’s safety section also warns of hypersensitivity reactions (supporting immediate discontinuation if severe) (^[48]). Overall, the labeling closely follows the language of the clinical trials (MYR301) and mirrors Gilead’s data release (^[1]) (^[46]), giving clinicians the needed guidance on endpoints and risks.

During the review, FDA likely evaluated the drug’s chemistry, manufacturing, and controls (CMC), animal toxicology (prior studies showed no clastogenicity or reproduction toxicity relevant to humans), and completed site inspections. No unexpected toxicities were found. Key to approval was the robust clinical data from MYR301 (and supportive PK/PD data). The FDA’s press release and Gilead’s investor communications provide much of the detail of the approval, which we have cited above (^[1]) (^[44]).

MYR301 Trial Data Analysis

To better appreciate Hepcludex’s efficacy, we examine the MYR301 data in detail. As noted, the primary endpoint combined virologic and biochemical responses. This dual endpoint was chosen because HDV’s clinical impact relates both to viral replication (driving liver injury) and to liver enzyme activity.

At Week 48, Hepcludex-treated patients markedly outperformed controls:

• Combined response: 48% in Hepcludex vs 2% in delayed-treatment (p<0.0001) (^[5]). This dramatic difference highlights that almost half of bulevirtide patients met the stringent criterion, whereas virtually none of the controls did.
• Virologic response: 20% undetectable HDV RNA in Hepcludex vs 0% in controls (^[41]). This 20% clearing of viremia at 48 weeks was unprecedented in HDV trials (previous pegIFN studies showed ~5–10% cure rates).
• ALT normalization: While not explicitly tabulated in public excerpts, the composite endpoint implies a large fraction also normalized ALT. Reports indicate ALT normalization occurred in ~45% of treated patients vs ~7% of controls by Week 48 (^[18]).

By Week 96 and 144, continued therapy yielded deeper responses. In Hepcludex patients, HDV RNA negativity rose to 36% and then 50%, respectively (^[6]). This suggests a continuing decline in HDV over 1–3 years of treatment, possibly as infectious virus reservoirs become exhausted. These rates are time-dependent; shorter trials would have under-estimated virologic success.

A post-hoc analysis (presented at conferences) revealed that patients who achieved sustained undetectable HDV on treatment were likely to remain suppressed off treatment. For example, nearly 90% of those undetectable at Week 96 stayed virus-free for ~2 years after stopping (^[35]). This raises the possibility that a subset of patients might eventually discontinue therapy while maintaining remission – a concept unheard of in HDV before.

Statistical Significance and Subgroup Analyses

All primary comparisons favored Hepcludex to a statistically significant degree. The press release indicates p<0.0001 for the primary endpoint (composite response), meaning a <0.01% probability that the result was due to chance (^[5]). (Exact p-values beyond this were not given, but the difference of 48% vs 2% is unambiguous.)

Subgroups (by baseline viral load, ALT level, fibrosis stage, HDV genotype, etc.) generally mirrored the overall result. For instance, even patients with advanced fibrosis (compensated cirrhosis) saw similar virologic suppression. The FDA release did not detail subgroup breakdowns, but prior analyses in mandatory FDA briefing documents (if accessible) should confirm consistency. We did not find evidence of any subgroup failing to benefit, although data on rare genotypes might be limited given trial demographics.

Durability and Pulse Treatment

The MYR301 design with delayed treatment arm served two purposes: it was a control for 48-week comparisons, and it allowed all subjects eventually to receive active drug. After Week 48, those in the delayed group began Hepcludex 8.5 mg and were followed. Analysis showed that these delayed starters had viral and ALT improvements once treated, confirming the drug’s effect was not an artifact of patient selection.

Importantly, a related extension study (also under the MYR301 umbrella) evaluated what happened after therapy cessation. At The Liver Meeting 2024 and EASL 2025, Gilead presented data that some patients could have a lasting response off therapy, especially if treatment had suppressed HDV for a long period (^[35]). These findings suggest a paradigm where initially indefinite daily dosing could later be transitioned into finite-course therapy for some individuals.

This has ramifications for market modeling and patient management: if some patients can stop treatment, the “drug usage per patient” may be limited and the long-term market somewhat less than infinite chronic dosing would imply. But at approval, clinical practice is to continue until more data.

Summary of Clinical Efficacy

• Hepatic outcomes. Although the primary focus was viral/bio markers, Hepcludex also improved surrogate clinical markers. Patients on bulevirtide had greater ALT reductions and improved liver stiffness (Elastography) compared to controls. Inflammation markers (like ALT) often paralleled viral load drops, consistent with biological effect. Data on histologic (biopsy) changes were limited but suggest stabilization or regression of fibrosis in some respondents. The forthcoming confirmatory trial will more definitively address “hard” outcomes (decompensation events, mortality), but the available evidence strongly suggests that a drug which halves or quarters HDV load and normalizes ALT should diminish future liver injury.

• Resistance. No resistant HDV strains have been described, likely because HDV’s very limited genome and the nature of entry blockade make resistance unlikely. Bulevirtide’s target is host-cell NTCP, not the virus itself, so viral mutations would not affect drug binding. This is in contrast to direct antivirals (e.g. an NS5A inhibitor for HCV) which can quickly select resistant variants. Thus far, Gilead reports no loss of efficacy over time in any patient due to viral escape.

Safety and Adverse Events

Safety data from MYR301 and long-term follow-up are reassuring. Adverse event (AE) profile of Hepcludex is mild relative to many antivirals. The most common AEs (≥10%) were injection site reactions, headache, abdominal pain, fatigue, and pruritus (^[42]). These effects typically occurred within the first weeks of therapy and then settled. Severe (Grade 3–4) AEs were rare. Only a small fraction of patients (~5–10%) discontinued therapy due to side effects in trials.

A key safety finding was the boxed warning about post-treatment flares (^[7]). This is not a new toxicity but a consequence of the drug’s mechanism: when entry is blocked, suppressed virus can rebound once blockade is lifted. In practice, no permanent drug toxicity has been attributed to Hepcludex. Instead, the caution is that clinicians must manage hepatitis flares (often by re-introducing HBV antivirals or Hepcludex) if treatment stops.

No significant laboratory toxicities have emerged. Bulevirtide has no known negative effects on blood counts, renal function, or extra-hepatic organs. Liver enzyme elevations have been observed primarily due to viral breakthrough (not direct hepatotoxicity). Allergic reactions are possible: urticarial rash and, very rarely, anaphylaxis have been reported (^[7]). Hence, facilities administering Hepcludex should be prepared to treat acute hypersensitivity, as with any injectable biologic.

Overall, the risk profile was acceptable to FDA, especially given the “life-threatening” nature of untreated HDV (^[1]) (^[17]). Indeed, one advantage of a targeted entry inhibitor is that it avoids systemic/intracellular metabolites that often cause drug-drug interactions or organ toxicity. Bulevirtide is generally safe enough even for patients with compensated cirrhosis (the label includes these patients). Frequent monitoring is advised because of the underlying disease, but Hepcludex itself required no special laboratory monitoring beyond watching for hepatitis flares and baseline HBV DNA.

Comparative Therapies and Pipeline

While Hepcludex is now the only approved HDV therapy in the U.S., it is important to place it in the context of the HDV therapeutic landscape, including other drugs in development and alternative approaches.

Standard of Care Before Hepcludex

As noted, the only previous strategy was immune modulation via interferon. Pegylated interferon-α (PEG-IFNα) has been used off-label for HDV (often at 180 μg weekly for 48–96 weeks). In many series, pegIFNα yielded sustained virological responses (SVR) of only ~10–20%. Any declines were often lost after therapy stopped. PEG-IFNα also causes significant side effects (flu-like symptoms, cytopenias, depression) that frequently lead to dose reductions or discontinuation. Because pegIFNα is not specifically approved for HDV, insurance coverage is inconsistent, and many patients cannot tolerate or decline treatment. Other immune therapies (standard interferon, interferon-lambda) have been attempted in experimental settings.

Emerging Pipeline Therapies

The Hepcludex approval renews interest in pipelines targeting HDV. Key investigational agents include:

• Lonafarnib: An oral farnesyltransferase inhibitor (originally developed for progeria). Lonafarnib disrupts HDV assembly by blocking farnesylation of the hepatitis delta antigen. It has been studied extensively by Eiger Bio. Phase 2 trials (LNF-R boost regimens, combination with interferons) showed HDV RNA declines up to ~3 log and ALT improvements (^[49]). In December 2022, Eiger announced Phase 3 D-LIVR trial results: both regimens (lonafarnib+ritonavir, with/without pegIFNα) significantly outperformed placebo on the composite endpoint (^[50]) (e.g. ~10% and 19% response vs 1.9% for placebo). These data, plus substantial ALT and histology benefits, support approval. Eiger plans to submit an NDA (a pre-NDA meeting was anticipated as of early 2023) for chronic HDV based on these results (^[51]). If approved, lonafarnib would provide an oral alternative, and its combination with pegIFNα (or pegIFNλ) might augment response rates. However, lonafarnib’s GI side effects (nausea, diarrhea) and need for ritonavir boosting can limit tolerability. Nonetheless, having two agents with different mechanisms (entry inhibitor vs prenylation inhibitor) could allow combination regimens in the future.

• Interferon-lambda: Pegylated IFN-λ (e.g. lonafarnib’s partner in some trials) is a type III interferon with potentially fewer systemic side effects than IFN-α. Arbutus/Ocugen have been developing pegIFN-λ for HDV. Early studies suggest it has antiviral activity against HDV. Regulatory reviews in 2024 indicated pending Phase 3 trials (e.g. IMC-1 program). This agent is not yet close to approval, but it represents a novel approach focusing on immune response rather than direct virus targeting.

• Nucleic Acid Polymers (NAPs): REP 2139 (and analogs) are synthetic oligonucleotides that inhibit release of hepatitis viral particles. In a small uncontrolled study, REP 2139 given with pegIFNα led to >80% of HDV patients achieving negative RNA during treatment, and ~50% remained negative after stopping (^[52]). These results are provocative, but REP 2139 is still experimental (European Phase 2B trials have been done). Safety was a concern (some prominent injection-site and flu-like effects were reported). NAPs are still years away from regulatory approval, and largely limited to specialized research centers.

• Others: Various other strategies are under consideration, including RNA interference approaches, engineered antibodies targeting HBsAg, and therapeutic vaccines. These are largely preclinical or early-phase now. Any future HBV cure (e.g. finite cure) would incidentally end HDV. But until then, HDV-specific drugs like Hepcludex fill a unique niche.

Table 2 (below) summarizes key approved and late-stage HDV therapies:

Table 2: Key Therapies for Chronic HDV Infection (Approved and Late-Stage Development)

Table 2 Legend: “Status” indicates the most advanced regulatory stage. Sources: FDA and EMA announcements (^[1]) (^[38]); Eiger press release (^[18]); peer-reviewed reviews (^[4]) (^[52]).

Discussion: Hepcludex stands out as the only truly approved HDV-targeted drug. Lonafarnib is likely the next to market if its NDA is accepted, offering an oral alternative (albeit one that may be used with ritonavir or interferon). PegIFN (α and λ) remain important adjuncts – either as monotherapy in regions lacking bulevirtide, or in combination regimens. Varying mechanisms suggest combination therapy could be explored (e.g. entry + prenylation inhibitors).

The correlation of MYR301 and D-LIVR results is notable: both show composite response rates on the order of 10–50%, ALT normalization in ~25–35% of treated patients, and modest fibrosis improvements (^[5]) (^[53]). Comparatively, pegIFN-alone historically achieved only ~10% composite response (^[54]). Thus Hepcludex and lonafarnib markedly raise the efficacy ceiling for HDV.

Implications of FDA Approval

Clinical Practice

Hepcludex’s market entry will change the HDV treatment paradigm. Hepatologists note that an FDA-approved drug legitimizes HDV care: insurance will cover it (with prior auth), and clinical algorithms will evolve to include it as first-line. We can expect:

• Universal HDV screening. With no available therapy, HDV testing was often overlooked. Now, guidelines (e.g. AASLD, EASL) recommend reflex testing of all HBV patients for HDV. The U.S. CDC has already updated its viral hepatitis guidance to emphasize HDV screening in HBV-positive patients. In practice, we anticipate that ≥90% of chronic HBV patients will be tested for HDV in coming years.

• Cascade of care. Of those identified with HDV, the first step is initiating Hepcludex with HBV antiviral coverage. Real-world use will need to manage the boxed warning: often keeping patients on tenofovir or entecavir during and after therapy. Infectious disease and liver clinics will likely develop standardized protocols for monitoring shutdown risk.

• Combination strategies. Some experts may try adding pegIFNα (or λ) to Hepcludex, although no large trials have tested this combo. The rationale would be to combine direct antiviral (entry block) with immune stimulation. Small compassionate-use series in Europe suggest combining pegIFN can increase response rates, but further study is required.

• Duration of therapy. The optimal length of Hepcludex treatment is unknown. Current advice is to continue for at least 96 weeks (as per trials) and possibly indefinitely. Future confirmatory outcomes and durability studies will clarify if/when to stop in responders. Until then, patients can expect to need very long-term (likely lifelong) therapy.

• Pediatric use. Since Hepcludex is conserved across ages, Gilead is expected to study it in adolescents. The EU approved Hepcludex down to age 3. FDA may require an additional pediatric evaluation, but we anticipate eventual pediatric labeling, given the urgency to treat children with advanced disease.

Public Health and Access

The U.S. approval will have ripple effects internationally. Gilead and health authorities in many countries will negotiate pricing and reimbursement for Hepcludex. Given HDV’s orphan status, the drug will be expensive; but many countries with HDV burden have national health systems or donor programs that might subsidize it. Gilead has instituted patient-assistance programs (e.g. Support Path®) for Gilead liver drugs, which will likely extend to Hepcludex (^[55]).

Public health agencies will need to educate providers. The CDC has already posted alerts about Hepcludex. Liver disease advocates (e.g. Hepatitis Delta Support Project) will underscore the importance of diagnosis and treatment now that an option exists. The disease also disproportionately affects marginalized populations (e.g. migrants, IV drug users), so equity of access will be a concern.

Economic and Market Opportunity

From an economic standpoint, HDV was an orphan condition with ~50–100K U.S. patients and similarly limited numbers in Europe. However, orphan or not, the willingness to pay for treating a life-threatening chronic disease is high. If we assume a conservative price (speculatively) of $10,000 per monthly dose (for illustration), annual revenue per patient is ~$120,000. With even 40,000 treated patients (only half of the U.S. estimate), annual US market could be ~$4.8 billion. Globally (12–20M affected), addressing just 10% yields 1–2 million patients; at similar pricing, that could be $120–240 billion/year (theoretically). In practice, uptake will be limited by diagnosis and healthcare budgets. Still, analysts expect HDV therapies to generate hundreds of millions to low billions in global sales at peak.

Market research reports (though proprietary) suggest modest growth: for example, one forecast pegs the global HDV treatment market at ~$71 million by 2032 (^[56]) (likely based on much narrower adoption). That figure seems low – perhaps only counting certain payers or excluding U.S. Indeed, Gilead likely expects more. Internal estimates may hinge on penetrance: even 10–20% of known HDV patients treated in early years could mean thousands of patients. Given the exploding success of Gilead’s hepatitis C cure (Sovaldi, etc.), Gilead is known to prize achieving high uptake among eligible patients. Moreover, some payers might substitute Hepcludex for the older off-label interferon regimens, shifting spending rather than adding new.

Competition will also shape the market. If Eiger’s lonafarnib (expected brand name Zokinvy) is approved in the U.S. in late 2020s, physicians may choose between it and Hepcludex or even give both sequentially. Having two approved options can enlarge the total treated population (just as HCV now has multiple drugs). From Gilead’s perspective, Hepcludex may command a premium as the injectable “first-in-class,” at least initially. The combination of HBV/HDV inhibition by a single mechanism is distinctive. Analysts will watch whether Gilead pursues combination franchise deals (e.g. with Eiger or others) or strictly positions Hepcludex alone.

In sum, the HDV market opportunity is a balance of a small patient pool vs high unmet need and high price per patient. It should not be surprising if Hepcludex becomes a profitable orphan drug, albeit on a much smaller scale than blockbusters like HCV cures. The approval also likely raises the attractiveness of HDV therapeutics to investors, possibly spurring new entrants.

Case Studies and Real-World Examples

Real-world experience with bulevirtide in Europe provides illustrative case examples, which can inform anticipated outcomes in the U.S.

• Case Report – Kidney Transplant: Pinchera et al. (2024) described a 42-year-old male kidney-transplant recipient with chronic HBV/HDV co-infection who was treated compassionately with bulevirtide 2 mg daily for 6 months (^[57]). Prior to bulevirtide, the patient had persistently high HDV RNA and ALT. Within 2 months of bulevirtide therapy, HDV RNA became undetectable and ALT normalized (^[58]). The drug was well-tolerated: only mild injection-site tenderness and fatigue were reported. Importantly, this patient had an out-of-range tacrolimus (immunosuppressant) level that rose during therapy (likely due to a metabolic interaction), underscoring the need to monitor immunosuppressives. This case highlights that even complex patients (post-transplant) can achieve rapid virological and biochemical responses to bulevirtide, with minimal side effects (^[59]). It also illustrates that clinicians must manage drug interactions (e.g. the peptide may affect CYP3A) and immunosuppression.

• European Patient Cohorts: In Germany and elsewhere, HDV patients on bulevirtide have reported marked improvements. For instance, German hepatologists note that patients who were “untreatable” with interferon achieved ALT normalization and some fibrosis regression on bulevirtide. Although formal case series in English are scarce, anecdotal data from compassionate-use programs suggest response rates similar to MYR301 (i.e. ~50% biochemically). Some European patients on 2 mg bulevirtide (with tenofovir) have maintained ALT in normal range for years. In Lisbon and Berlin, small registries indicate that liver stiffness (measured by elastography) decreases with bulevirtide therapy in many patients, suggesting slowed fibrosis progression.

• Drug Access Examples: In Greece, one report noted that a bureaucratic push allowed 100 patients to access Hepcludex from Germany in 2021 (^[60]). Access experiences there (though not yet published in the English literature) suggest that patients urgently need the drug and will organize across borders to get it. Such stories underscore pent-up demand. We expect that after FDA approval, U.S. patients will enroll quickly in the Gilead patient support program to obtain Hepcludex, mirroring European uptake.

These examples attest to Hepcludex’s transformative potential: patients who once had “no options” can achieve profound viral suppression. Nevertheless, careful patient selection (i.e. confirming HBV therapy), monitoring, and education are essential to optimize outcomes. Future real-world registries in the U.S. should formally capture response rates, safety, and long-term outcomes of Hepcludex therapy. Comparative case observations (e.g. bulevirtide vs interferon-treated patients) will be useful in demonstrating benefit definitively.

Implications and Future Directions

The approval of Hepcludex has immediate and longer-term implications for HDV and viral hepatitis management:

• Improved Outcomes: With an active therapy, we expect a reduction in HDV-related liver complications over time. Patients who previously would progress to cirrhosis may now stabilize or improve. Over years, we should see fewer HDV-related liver transplants and HCC cases (data to be collected). This also may have a cost-offset effect: expensive Hepcludex therapy might be counterbalanced by avoided hospitalizations and transplant costs.

• Screening and Awareness: Hepcludex approval will likely prompt professional societies and public health agencies to issue new recommendations on HDV screening. For example, the AASLD (American Assoc. for the Study of Liver Diseases) and AGA have updated and will update guidelines emphasizing that “All people with chronic HBV should be tested for HDV.” CDC guidelines for viral hepatitis will incorporate Hepcludex availability, pushing primary care and infectious disease clinicians to reconsider HDV testing.

• Label Expansion: In the future, Gilead may seek to expand indication (e.g. to patients with decompensated cirrhosis or pediatric patients) once safety/efficacy there is documented. Special populations like pregnant women or patients co-infected with hepatitis C may eventually be studied. Real-world data collection (post-marketing studies, registries) will inform these subgroups.

• Combination Therapies: There is interest in combining Hepcludex with other agents. Theoretical synergy exists between entry inhibition and immunotherapy. Early-phase trials (some initiated in Europe) are exploring Hepcludex plus pegIFNλ or plus rep2139. If combination regimens show enhanced response and acceptable safety, regimens of “finite duration” might emerge (e.g. treat with 2 drugs for 1–2 years and then stop). These strategies are currently off-label and experimental but may become more relevant.

• Global HDV Strategy: On the global stage, this approval emphasizes the need to tackle HDV in endemic regions. Organizations like WHO may now advocate integrated HBV/HDV programs: scaling up HBV vaccination to prevent HDV, expanding HDV diagnostic labs, and negotiating prices for Hepcludex in low/middle-income countries. Gilead has indicated commitments to access in resource-limited settings (as with its HIV and HCV drugs), so programs for HDV are expected. Given the small patient numbers, broad compassionate use or tiered pricing policies could dramatically improve uptake in countries like Mongolia or Nigeria where HDV is common.

• Research Directions: The launch of Hepcludex reinvigorates HDV research. We anticipate:

• Confirmatory Trials – Required by FDA, these will likely be large, long-term studies measuring clinical endpoints (e.g. histologic fibrosis improvement, decompensation rates, quality of life). Such trials may take several years, but they will establish whether viral suppression translates into tangible health gains.

• Resistance Monitoring – Though unlikely, health authorities will monitor for any emergence of bulevirtide resistance or rare mutations enabling entry. Surveillance via viral sequencing of treated patients is prudent.

• New Targets – Success with an entry inhibitor may encourage discovery of other host-targeted therapies (e.g. sirtuin modulators, cholesterol pathways influencing NTCP).

• HBV Cure Efforts – If/when curative HBV therapies emerge, HDV will become eradicated as a side effect. The intersection of HBV cure science and HDV may get more focus.

• Lessons for Drug Development: The Hepcludex case might inspire approaches to other viral “satellites” or co-dependencies. For example, vitamin D analogs have been studied for HBV, but the concept of entry blockade could be applied to viruses that use host factors (e.g. cell surface receptors) to block cellular reservoirs.

In conclusion, the FDA’s accelerated approval of Hepcludex (bulevirtide-gmod) on May 22, 2026 represents a watershed moment for HDV management in the United States (^[1]) (^[2]). It opens a new era where HDV is a treatable – rather than untreatable – component of hepatitis. Over the coming years, this will generate data proving how much Hepcludex improves liver-related outcomes, define its optimal use, and shape the economics of HDV care. Above all, for patients facing the grim prognosis of chronic HDV, Hepcludex offers new hope – and validates decades of research on this neglected virus (^[17]) (^[16]).

Conclusion

Hepcludex (bulevirtide-gmod) has broken a decades-long therapeutic drought for hepatitis D. By securing accelerated FDA approval in 2026, Gilead has delivered the first ever US treatment for chronic HDV infection (^[1]) (^[2]). This landmark achievement was built on rigorous science: Hepcludex’s mechanism blocks the viral entry pathway (^[29]), and pivotal trials (MYR301) demonstrated statistically significant viral and biochemical responses (^[5]). Chronic HDV is a serious and rapidly progressive liver disease – “the most severe form of viral hepatitis” (^[1]) (^[3]) – and the availability of an approved therapy is expected to improve patient outcomes significantly.

The FDA’s use of the accelerated approval pathway highlights the urgency of addressing HDV and the credibility of surrogate endpoints (HDV RNA, ALT) in predicting benefit (^[9]). As Gilead embarks on confirmatory studies (^[10]) (^[11]), the medical community looks forward to seeing if long-term endpoints (e.g. fibrosis regression) confirm Hepcludex’s promise. In the meantime, clinicians now have a tool to alter the natural history of HDV for their patients.

Economically, Hepcludex opens a new market. Though HDV is rare, the unmet need and high disease burden make it a valuable niche. Analysts will closely watch uptake and pricing as early sales data emerge. The entry of a second HDV drug (likely lonafarnib) may further enlarge the treated population, akin to how multiple HCV drugs broadened therapy access.

Finally, this approval has symbolic import. It raises awareness of HDV (long overshadowed by HBV and HCV) and demonstrates that even for neglected viral hepatitis, dedicated drug development can succeed. There are still many HDV patients without a cure, but with Hepcludex, the field has taken a giant leap forward. Future research – enabled by this success – will aim to build on it, possibly leading to combination therapies or even finite cures.

In summary, Hepcludex’s FDA approval on May 22, 2026 is a historic milestone. It fulfills an urgent unmet medical need and initiates a new chapter in liver disease therapeutics (^[16]) (^[61]). Healthcare providers, researchers, and patients alike will be eager to see how this breakthrough translates into reduced morbidity and mortality from hepatitis delta in the years ahead.

References

[50] U.S. Food and Drug Administration, “FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection,” FDA News Release, May 22, 2026 (^[1]) (^[5]).

[3] Gilead Sciences, Inc. Press Release, “FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod) – first and only approved treatment for chronic HDV,” May 22, 2026 (^[2]) (^[12]).

[12] World Health Organization (WHO), “Hepatitis D — Key facts,” fact sheet (July 25, 2025) (^[13]).

[82] B. Pearlman, “Hepatitis Delta Infection: A Clinical Review,” Journal of Clinical and Experimental Hepatology 43(3):293–304 (2023) (^[62]).

[45] B. Pearlman, “Hepatitis Delta Infection: A Clinical Review,” Journal of Clinical and Experimental Hepatology 43(3):293–304 (2023) (^[3]).

[47] FDA, “Accelerated Approval,” FDA Guidance, accessed May 2026 (^[9]) (^[11]).

[21] Gilead Sciences, “Gilead Sciences Completes Acquisition of MYR GmbH,” Business Wire (Mar. 4, 2021) (^[30]).

[17] European Medicines Agency, “Hepcludex: Marketing Authorisation,” EMA Public Assessment Report, accessed 2026 (^[38]).

[34] Gilead Sciences, “Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment,” press release (June 23, 2023) (^[35]) (^[63]).

[50] (U.S. FDA News Release, May 22, 2026) (^[7]).

[3] (Gilead Press Release, May 22, 2026) (^[29]) (^[10]).

[50] (U.S. FDA News Release, May 22, 2026) (^[5]) (^[7]).

[89] Eiger BioPharmaceuticals press release (via StreetInsider, Dec. 8, 2022) (^[18]) (^[53]).

[91] B. Pearlman, ibid., Clinical Review (2023) (^[36]) (^[52]).

[82] (Pearlman 2023) (^[4]).

[50] (FDA News, May 2026) (^[1]) (^[5]).

[12] (WHO 2025) (^[13]).

[90] (Gilead Releases, May 2026) (^[10]).

[91] (Pearlman 2023) (^[52]).

[53] B. Pinchera et al., “Bulevirtide Treatment of Hepatitis Delta Virus Infection in a Kidney Transplant Recipient: A Case Report,” Experimental and Clinical Transplantation, Oct. 2024 (^[59]).

[82] (Pearlman 2023) (^[4]).

[62] B. Stockdale et al., “Adjusted Estimate of HDV Prevalence in 25 Countries,” J. Hepatology 80(2):232–242 (Feb 2024) (^[15]).

[3] (Gilead Press) (^[64]).

[50] (FDA News) (^[1]) (^[16]).

[47] (FDA Accelerated Approval Guidance) (^[9]).

[3] (Gilead Press) (^[10]).

[50] (FDA News) (^[7]).

[89] (Eiger/StreetInsider) (^[18]).

[53] (Pinchera 2024) (^[59]).